Irinotecan is among the top four small-molecule drugs with the highest binding affinity to the CLK2 binding pocket, and it has been widely used in clinical trials for solid tumors, such as colorectal, pancreatic, and biliary tract cancers (36–38). This evidence concerns the gene CLK2 and biliary tract cancer.